photo
Speaker

Paul Peter Tak, MD, PhD

PRESIDENT & CEO, KINTAI THERAPEUTICS
Cambridge, Massachusetts, United States
Paul Peter Tak is President, CEO and Board Member of Kintai Therapeutics and Venture Partner at Flagship Pioneering (both in Cambridge, MA).

He received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years. His scientific work in academia includes the discovery of the cholinergic anti-inflammatory pathway (inflammatory reflex) in chronic inflammation. He has published extensively in peer-reviewed journals (570 publications, H-index 127, >70,000 citations), received numerous awards, and has been elected Fellow of the Academy of Medical Sciences in the U.K.

At GlaxoSmithKline he served as Senior Vice President, Chief Immunology Officer, and Global Development Leader. He oversaw the creation of a portfolio of potential medicines for immune-mediated inflammatory diseases and pain, including anti-OSM antibody, anti-LAG3 antibody, ESM-BET inhibitor, RIP1 kinase inhibitor, anti-GM-CSF antibody, anti-CCL17 antibody and Benlysta sc. Later, he also led the Infectious Disease and Oncology Therapy Area Units and oversaw the creation of new portfolio of medicines for patients with cancer, including the anti-BCMA antibody-drug conjugate.

He has been CEO of Tempero Pharmaceuticals (Cambridge, MA), Board Member of Galvani Bioelectronics and ViiV Healthcare (both in London). He is one of the Founders and Board Directors of Sitryx Therapeutics (Oxford), and serves on the Board of Directors of Kintai Therapeutics (Cambridge, MA), Levicept (London) and Omega Therapeutics (Cambridge, MA).
Speaking In
[Available On-Demand]
Kintai Therapeutics is uniquely focused on unlocking the power of the enteric signaling network and…